VAV1 Degrader Enters Second Phase II Disease
Monte Rosa said on 28 October that Novartis initiated a second Phase II study of licensed VAV1 molecular-glue degrader MRT-6160, also called DDY391, in psoriatic arthritis. This is development expansion and a milestone event,…
